{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:09:45Z","timestamp":1787022585903,"version":"build-2736575974"},"reference-count":26,"publisher":"Walter de Gruyter GmbH","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jpm-2020-0106_abs_001_w2aab3b7c60b1b6b1aab1c15b1Aa\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare pregnancy outcomes with medication assisted treatment using. methadone or buprenorphine in term mothers with opioid use disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpm-2020-0106_abs_002_w2aab3b7c60b1b6b1aab1c15b2Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cohort of women receiving medication assisted treatment with either methadone or buprenorphine were identified from delivery records over a 10\u2010year period. Women were excluded with delivery\u00a0&lt;37\u00a0weeks, multiple gestations, or a known anomalous fetus. Maternal demographics, medications, mode of delivery, birthweight, newborn length of stay, and neonatal abstinence syndrome were extracted. The study was IRB approved and a p-value of\u00a0&lt;0.05 was significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpm-2020-0106_abs_003_w2aab3b7c60b1b6b1aab1c15b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 260 women, 140 (53.8%) with methadone use and 120 (46.2%) with buprenorphine use. Groups were similar for maternal age, race, parity, homeless rate, tobacco use, mode of delivery and incidence of neonatal abstinence syndrome. The methadone group had a lower mean newborn birthweight (2874\u00b1459\u00a0g) and a greater incidence of low birth weight (11.4%) than the buprenorphine group (3282\u00b1452\u00a0g; p&lt;0.001 and 2.5%; p=0.006). The incidence of neonatal abstinence syndrome was similar between groups (97% methadone vs. 92.5% buprenorphine; p=0.08). The methadone group had a longer newborn length of stay (11.4+7.4\u00a0days) and more newborn treatment with morphine (44.6%) than the buprenorphine group (8.2+4.4\u00a0days; p&lt;0.001 and 24.2%; p&lt;0.001). Maternal methadone use was an independent predictor for a newborn length of hospital stay\u00a0&gt;7\u00a0days (OR 3.61; 95% confidence interval 1.32\u20139.86; p=0.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpm-2020-0106_abs_004_w2aab3b7c60b1b6b1aab1c15b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Medication assisted treatment favors buprenorphine use when compared to. methadone with an increased birthweight, reduced need for newborn treatment, and a shorter newborn length of stay in term infants.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jpm-2020-0106","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T09:31:36Z","timestamp":1595410296000},"page":"677-680","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of buprenorphine and methadone in the management of maternal opioid use disorder in full term pregnancies"],"prefix":"10.1515","volume":"48","author":[{"given":"Cara L.","family":"Staszewski","sequence":"first","affiliation":[{"name":"Department of Obstetrics & Gynecology and Reproductive Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Garretto","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology and Reproductive Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan T.","family":"Garry","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology and Reproductive Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Ly","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology and Reproductive Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay A.","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology and Reproductive Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly M.","family":"Herrera","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology and Reproductive Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","reference":[{"key":"ref91","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa1005359","article-title":"Neonatal abstinence syndrome after methadone or buprenorphine exposure","volume":"363","year":"2010","journal-title":"N Engl J Med"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"459.e1","DOI":"10.1016\/j.ajog.2017.06.029","article-title":"An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy","volume":"217","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/jp.2017.157","article-title":"Antenatal methadone vs buprenorphine exposure and length of hospital stay in infants admitted to the intensive care unit with neonatal abstinence syndrome","volume":"38","year":"2018","journal-title":"J Perinatol"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jsat.2017.12.003","article-title":"Associations between pharmacotherapy for opioid dependence and clinical and criminal justice outcomes among adults with co-occurring serious mental illness","volume":"86","year":"2018","journal-title":"J Substain Abuse Treat"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2004.11.013","article-title":"Buprenorphine versus methadone in the treatment of pregnant opioid dependent patient: effects on the neonatal abstinence syndrome (PROMISE Study)","volume":"79","year":"2005","journal-title":"Drug Alcohol Depend"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa1005359","article-title":"Neonatal abstinence syndrome after methadone or buprenorphine exposure (MOTHER Study)","volume":"363","year":"2010","journal-title":"N Engl J Med"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/ADM.0000000000000092","article-title":"Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study","volume":"9","year":"2015","journal-title":"J Addict Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3109\/00952990.2015.1059625","article-title":"Methadone versus buprenorphine for the treatment of opioid abuse in pregnancy: science and stigma","volume":"41","year":"2015","journal-title":"Am J Drug Alcohol Abuse"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"459.e1","DOI":"10.1016\/j.ajog.2017.06.029","article-title":"An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy","volume":"217","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"ref131","first-page":"1070","article-title":"ACOG Committee Opinion No. 524: ACOG Committee on Health Care for Underserved Women; American Society of Addiction Medicine","volume":"119","year":"2012","journal-title":"Obstet Gynecol"},{"key":"ref161","first-page":"185","article-title":"Buprenorphine and naloxone versus buprenorphine for opioid use disorder in pregnancy: a Cohort Study","volume":"14","year":"2019","journal-title":"J Addict Med"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/jp.2017.157","article-title":"Antenatal methadone vs buprenorphine exposure and length of hospital stay in infants admitted to the intensive care unit with neonatal abstinence syndrome","volume":"38","year":"2018","journal-title":"J Perinatol"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2006.01321.x","article-title":"Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study","volume":"101","year":"2006","journal-title":"Addiction"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jogc.2017.04.028","article-title":"No. 349-substance use in pregnancy","volume":"39","year":"2017","journal-title":"J Obstet Gynaecol Can"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/ADM.0000000000000092","article-title":"Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study","volume":"9","year":"2015","journal-title":"J Addict Med"},{"key":"ref31","first-page":"185","article-title":"Buprenorphine and naloxone versus buprenorphine for opioid use disorder in pregnancy: a Cohort Study","volume":"14","year":"2019","journal-title":"J Addict Med"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","article-title":"Medication treatment of opioid use disorder","volume":"87","year":"2020","journal-title":"Biol Psychiatry"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2004.11.013","article-title":"Buprenorphine versus methadone in the treatment of pregnant opioid dependent patient: effects on the neonatal abstinence syndrome (PROMISE Study)","volume":"79","year":"2005","journal-title":"Drug Alcohol Depend"},{"key":"ref01","first-page":"1070","article-title":"ACOG Committee Opinion No. 524: ACOG Committee on Health Care for Underserved Women; American Society of Addiction Medicine","volume":"119","year":"2012","journal-title":"Obstet Gynecol"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa1005359","article-title":"Neonatal abstinence syndrome after methadone or buprenorphine exposure","volume":"363","year":"2010","journal-title":"N Engl J Med"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa1005359","article-title":"Neonatal abstinence syndrome after methadone or buprenorphine exposure (MOTHER Study)","volume":"363","year":"2010","journal-title":"N Engl J Med"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jogc.2017.04.028","article-title":"No. 349-substance use in pregnancy","volume":"39","year":"2017","journal-title":"J Obstet Gynaecol Can"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jsat.2017.12.003","article-title":"Associations between pharmacotherapy for opioid dependence and clinical and criminal justice outcomes among adults with co-occurring serious mental illness","volume":"86","year":"2018","journal-title":"J Substain Abuse Treat"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3109\/00952990.2015.1059625","article-title":"Methadone versus buprenorphine for the treatment of opioid abuse in pregnancy: science and stigma","volume":"41","year":"2015","journal-title":"Am J Drug Alcohol Abuse"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2006.01321.x","article-title":"Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study","volume":"101","year":"2006","journal-title":"Addiction"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","article-title":"Medication treatment of opioid use disorder","volume":"87","year":"2020","journal-title":"Biol Psychiatry"}],"container-title":["Journal of Perinatal Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/jpme\/48\/7\/article-p677.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2020-0106\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T21:37:49Z","timestamp":1619041069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2020-0106\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":26,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.1515\/jpm-2020-0106","relation":{},"ISSN":["1619-3997","0300-5577"],"issn-type":[{"value":"1619-3997","type":"electronic"},{"value":"0300-5577","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,25]]}}}